XML 28 R18.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Shareholders' Equity | 9 Months Ended
--- | ---
Feb. 01, 2025
Share-Based Payment Arrangement [Abstract] |
Shareholders' Equity | Note 9. Shareholders’ Equity Repurchases of Common Stock On March 31, 2021, as subsequently amended on June 16, 2022, the Board of Directors authorized the purchase of up to $200.0 million of the Company’s outstanding common stock through June 14, 2024 (the “2021 Buyback Authorization”). On June 13, 2024, the Board of Directors approved a new share buyback authorization, commencing on June 17, 2024, for the purchase of up to $200.0 million of the Company’s outstanding common stock through June 17, 2026 (the “2024 Buyback Authorization”). Purchases may be made on the open market, including pursuant to purchase plans designed to comply with Rule 10b5-1 of the Securities Exchange Act of 1934, or in private transactions. The following table summarizes activity under the 2021 Buyback Authorization:
|  | Three Months Ended |  |  | Nine Months Ended |
|  | February 1, 2025 |  |  | January 27, 2024 |  |  | February 1, 2025 |  |  | January 27, 2024 |
(in millions, except share and per share data) |  | (13 Weeks) |  |  | (13 Weeks) |  |  | (40 Weeks) |  |  | (39 Weeks) |
Shares purchased |  |  | — |  |  |  | 130,592 |  |  |  | 136,000 |  |  |  | 453,371 |
Average price per share |  | $ | — |  |  | $ | 22.99 |  |  | $ | 11.55 |  |  | $ | 23.73 |
Total cost |  | $ | — |  |  | $ | 3.0 |  |  | $ | 1.6 |  |  | $ | 10.8 |
Prior to its expiration, a total of 3,553,961 shares were purchased under the 2021 Buyback Authorization at a total cost of $134.6 million. All purchased shares were retired and are reflected as a reduction of common stock for the par value of shares, with the excess applied as a reduction to retained earnings. In the three and nine months ended February 1, 2025, there were zero and 136,000 shares purchased under the 2021 Buyback Authorization and no shares purchased under the 2024 Buyback Authorization. No further shares can be purchased under the 2021 Buyback Authorization. As of February 1, 2025, the dollar value of shares that remained available to be purchased by the Company under 2024 Buyback Authorization was $200.0 million. Dividends The Company paid dividends totaling $5.3 million and $4.9 million in the three months ended February 1, 2025 and January 27, 2024, respectively. The Company paid dividends totaling $15.3 million and $15.0 million in the nine months ended February 1, 2025 and January 27, 2024, respectively. Dividends paid in the three months ended February 1, 2025 include $0.6 million of dividend equivalent payments for restricted stock units that vested. Dividends paid in the nine months ended February 1, 2025 and January 27, 2024, include $0.8 million and $0.4 million of dividend equivalent payments for restricted stock units that vested. Accumulated other comprehensive income (loss) Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. A summary of changes in AOCI, net of tax is shown below:
|  | Three Months Ended February 1, 2025 (13 Weeks) |  |  | Nine Months Ended February 1, 2025 (40 Weeks) |
(in millions) |  | Currency translation adjustments |  |  | Derivative instruments |  |  | Total |  |  | Currency translation adjustments |  |  | Derivative instruments |  |  | Total |
Balance at beginning of period |  | $ | (34.9 | ) |  | $ | (2.8 | ) |  | $ | (37.7 | ) |  | $ | (36.5 | ) |  | $ | (0.2 | ) |  | $ | (36.7 | )
Other comprehensive income (loss) |  |  | (13.3 | ) |  |  | 2.7 |  |  |  | (10.6 | ) |  |  | (12.5 | ) |  |  | (0.8 | ) |  |  | (13.3 | )
Tax (expense) benefit |  |  | (2.2 | ) |  |  | (0.7 | ) |  |  | (2.9 | ) |  |  | (1.4 | ) |  |  | 0.2 |  |  |  | (1.2 | )
Net other comprehensive income (loss) |  |  | (15.5 | ) |  |  | 2.0 |  |  |  | (13.5 | ) |  |  | (13.9 | ) |  |  | (0.6 | ) |  |  | (14.5 | )
Balance at the end of period |  | $ | (50.4 | ) |  | $ | (0.8 | ) |  | $ | (51.2 | ) |  | $ | (50.4 | ) |  | $ | (0.8 | ) |  | $ | (51.2 | )
|  | Three Months Ended January 27, 2024 (13 Weeks) |  |  | Nine Months Ended January 27, 2024 (39 Weeks) |
(in millions) |  | Currency translation adjustments |  |  | Derivative instruments |  |  | Total |  |  | Currency translation adjustments |  |  | Derivative instruments |  |  | Total |
Balance at beginning of period |  | $ | (42.5 | ) |  | $ | (0.4 | ) |  | $ | (42.9 | ) |  | $ | (19.8 | ) |  | $ | 0.8 |  |  | $ | (19.0 | )
Other comprehensive income (loss) |  |  | 11.7 |  |  |  | (2.8 | ) |  |  | 8.9 |  |  |  | (8.6 | ) |  |  | (4.3 | ) |  |  | (12.9 | )
Tax benefit (expense) |  |  | 2.0 |  |  |  | 0.8 |  |  |  | 2.8 |  |  |  | (0.4 | ) |  |  | 1.1 |  |  |  | 0.7 |
Net other comprehensive income (loss) |  |  | 13.7 |  |  |  | (2.0 | ) |  |  | 11.7 |  |  |  | (9.0 | ) |  |  | (3.2 | ) |  |  | (12.2 | )
Balance at the end of period |  | $ | (28.8 | ) |  | $ | (2.4 | ) |  | $ | (31.2 | ) |  | $ | (28.8 | ) |  | $ | (2.4 | ) |  | $ | (31.2 | )
Stock-based compensation The Company has granted stock options, restricted stock awards (“RSAs”), performance units (“PUs”), restricted stock units (“RSUs”), performance stock units (“PSUs”) and stock awards to employees and non-employee directors under the Methode Electronics, Inc. 2022 Omnibus Incentive Plan (“2022 Plan”), the Methode Electronics, Inc. 2014 Omnibus Incentive Plan (“2014 Plan”), the Methode Electronics, Inc. 2010 Stock Plan (“2010 Plan”), and the Methode Electronics, Inc. 2004 Stock Plan (“2004 Plan”). The Company can no longer make grants under the 2014 Plan, 2010 Plan and 2004 Plan. Subject to adjustment as provided in the 2022 Plan and the 2022 Plan’s share counting provisions, the number of shares of the Company's common stock that will be available for all awards under the 2022 Plan is 5,550,000, less an amount to reflect shares, options or other awards granted under prior plans after April 30, 2022. As of February 1, 2025, there were approximately 3.6 million shares available for award under the 2022 Plan. Restricted stock awards and performance units As of February 1, 2025, the Company had 710,349 RSAs outstanding which may be earned based on the achievement of an earnings before net interest, taxes, fixed asset depreciation and intangible asset amortization (“EBITDA”) measure for fiscal 2025. The RSAs will vest ranging from 0% (for performance below threshold) to 100% (target performance) based on the achievement of the EBITDA performance measure and continued employment. In addition, if the target performance is exceeded, up to an additional 355,175 PUs can be earned that will be settled in cash. The fair value of the RSAs was based on the closing stock price on the date of grant and the RSAs earn dividend equivalents during the vesting period, which are forfeitable if the RSAs do not vest. Compensation expense for the RSAs is recognized when it is probable the minimum threshold performance criteria will be achieved. Compensation expense for the PUs is recognized when it is probable that the target performance criteria will be exceeded. The Company assesses the probability of vesting at each balance sheet date and adjusts compensation costs based on the probability assessment. The cash-settled PUs represent a non-equity unit with a conversion value equal to the fair market value of a share of the Company’s common stock on the vesting date. The PUs are classified as liability awards due to the cash settlement feature and are re-measured at each balance sheet date. In accordance with ASC 718, “Compensation - Stock Compensation” based on projections of the Company’s current business portfolio, no compensation expense has been recognized for the RSAs or PUs to date, as the performance conditions are not probable of being met. Unrecognized stock-based compensation expense at target level of performance is $20.5 million as of February 1, 2025, which, subject to the performance conditions being met, will be recognized through fiscal 2025. The following table summarizes RSA activity:
|  | Restricted stock awards |  |  | Weighted average grant date fair value |
Non-vested at April 27, 2024 |  |  | 789,674 |  |  | $ | 28.81 |
Awarded |  |  | — |  |  | $ | — |
Vested |  |  | — |  |  | $ | — |
Forfeited |  |  | (79,325 | ) |  | $ | 28.28 |
Non-vested at February 1, 2025 |  |  | 710,349 |  |  | $ | 28.87 |
Performance stock units In the nine months ended February 1, 2025, the Company granted 208,661 PSUs which will vest upon the achievement of a total stockholder return (“TSR”) measure based on the growth in the Company’s stock price over a three-year performance period that ends April 30, 2027. The number of shares to be issued may range from 0% to a maximum of 200% of the PSUs granted. The Company estimated the grant date fair value of the PSUs using the Monte Carlo simulation model, as the TSR metric and changes in stock price are considered market conditions under ASC 718. The following table provides a summary of the weighted-average assumptions for the PSUs granted:
|  | Assumptions |
Expected volatility |  |  | 52.40 | %
Risk free interest rate |  |  | 4.07 | %
Expected term (in years) |  |  | 2.72 |
Grant date fair value |  | $ | 14.09 |
The PSUs earn dividend equivalents during the vesting periods, which are forfeitable if the PSUs do not vest. As of February 1, 2025, unrecognized share-based compensation expense for the PSUs was $2.5 million, which is expected to be recognized over a weighted average period of approximately three years. The following table summarizes PSU activity:
|  | Performance stock units |  |  | Weighted average grant date fair value |
Non-vested at April 27, 2024 |  |  | — |  |  | $ | — |
Awarded |  |  | 208,661 |  |  | $ | 14.09 |
Vested |  |  | — |  |  | $ | — |
Forfeited |  |  | — |  |  | $ | — |
Non-vested at February 1, 2025 |  |  | 208,661 |  |  | $ | 14.09 |
Restricted stock units RSUs granted vest over a pre-determined period of time, up to five years from the date of grant. The fair value of the RSUs granted are based on the closing stock price on the date of grant and earn dividend equivalents during the vesting periods, which are forfeitable if the RSUs do not vest. The following table summarizes RSU activity:
|  | Restricted stock units |  |  | Weighted average grant date fair value |
Non-vested at April 27, 2024 |  |  | 941,640 |  |  | $ | 26.43 |
Awarded |  |  | 326,244 |  |  | $ | 12.01 |
Conversion of cash bonus to RSUs |  |  | 160,401 |  |  | $ | 12.87 |
Vested |  |  | (396,744 | ) |  | $ | 28.29 |
Forfeited |  |  | (183,930 | ) |  | $ | 22.73 |
Non-vested at February 1, 2025 |  |  | 847,611 |  |  | $ | 18.25 |
In the nine months ended February 1, 2025, 160,401 RSUs were awarded in exchange for cash bonuses earned by certain employees. These RSUs vest on March 7, 2025. As the expense associated with the cash bonuses was previously recognized in fiscal 2024, there is no incremental expense to be recognized for the RSUs. The Company reclassified $2.1 million from accrued employee liabilities to additional paid-in capital on its condensed consolidated balance sheets related to the conversion of the cash bonuses to RSUs. Under the various stock plans, RSUs that have vested for certain executives, including Ronald L.G. Tsoumas, the Company’s former CFO, will not be delivered in common stock until the first day of the seventh month following the executive’s termination from the Company or upon a change of control. As of February 1, 2025, common stock to be delivered to these executives totaled 85,553 shares, of which 60,875 shares were delivered on February 4, 2025. The vested deferred RSUs are considered outstanding for earnings per share calculations. As of February 1, 2025, unrecognized share-based compensation expense for RSUs was $4.8 million which will be recognized over a weighted-average amortization period of 1.3 years. Director awards The Company grants stock awards to its non-employee directors as a component of their compensation. The stock awards vest immediately upon grant. Non-employee directors may elect to defer receipt of their shares under the Company’s non-qualified deferred compensation plan. The following table summarizes awards granted to non-employee directors:
|  | Non-employee director awards |  |  | Deferred non-employee director awards |  |  | Total |  |  | Weighted average grant date fair value |
Outstanding at April 27, 2024 |  |  | — |  |  |  | 77,319 |  |  |  | 77,319 |  |  | $ | 37.23 |
Awarded |  |  | 56,680 |  |  |  | 90,725 |  |  |  | 147,405 |  |  | $ | 9.92 |
Issued |  |  | (56,680 | ) |  |  | (23,756 | ) |  |  | (80,436 | ) |  | $ | 10.49 |
Outstanding at February 1, 2025 |  |  | — |  |  |  | 144,288 |  |  |  | 144,288 |  |  | $ | 22.80 |
Stock options The following table summarizes stock option activity:
|  | Stock options |  |  | Weighted average exercise price |  |  | Weighted- average life (years) |  |  | Aggregate intrinsic value (in millions) |
Outstanding and exercisable at April 27, 2024 |  |  | 8,000 |  |  | $ | 37.01 |  |  |  | 0.2 |  |  | $ | 0.0 |
Exercised |  |  | — |  |  | $ | — |  |  |  |  |  |  |
Forfeited |  |  | (8,000 | ) |  | $ | 37.01 |  |  |  |  |  |  |
Outstanding and exercisable at February 1, 2025 |  |  | — |  |  | $ | — |  |  |  | 0.0 |  |  | $ | 0.0 |
Stock-based compensation expense All stock-based awards to employees and non-employee directors are recognized in selling and administrative expenses on the condensed consolidated statements of operations. Awards subject to graded vesting are recognized using the accelerated recognition method over the requisite service period. The table below summarizes the stock-based compensation expense related to the equity awards:
|  | Three Months Ended |  |  | Nine Months Ended |
|  | February 1, 2025 |  |  | January 27, 2024 |  |  | February 1, 2025 |  |  | January 27, 2024 |
(in millions) |  | (13 Weeks) |  |  | (13 Weeks) |  |  | (40 Weeks) |  |  | (39 Weeks) |
RSUs |  | $ | 1.5 |  |  | $ | (2.1 | ) |  | $ | 3.5 |  |  | $ | 0.2 |
PSUs |  |  | 0.3 |  |  |  | — |  |  |  | 0.5 |  |  |  | — |
Deferred non-employee director awards |  |  | — |  |  |  | — |  |  |  | 0.9 |  |  |  | 1.0 |
Non-employee director awards |  |  | — |  |  |  | — |  |  |  | 0.6 |  |  |  | 0.6 |
Total stock-based compensation expense |  | $ | 1.8 |  |  | $ | (2.1 | ) |  | $ | 5.5 |  |  | $ | 1.8 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration